In addition, a number of similar clinical trials targeting immune checkpoints including PD1 and cytokine inducible SH2 containing protein (CISH) were conducted in patients with advanced esophageal cancer (NCT03081715), prostate cancer (NCT03525652), advanced stage Epstein-Barr virus (EBV) associated malignancies (NCT03044743), advanced Hepatocellular Carcinoma (NCT04417764), invasive bladder cancer (NCT02863913) and metastatic gastrointestinal cancers (NCT04426669). This evidence concerns the gene CISH and hepatocellular carcinoma.